2923284-73-3
Chemical Structure
Tovecimig
Synonym(s): CTX-009; ES 104
- CAS No.: 2923284-73-3
- Molecular Weight:(199.624 kDa)
SMILES: [Tovecimig]
Biological Activity: Tovecimig (CTX-009) is a bispecific antibody targeting DLL4 and VEGF-A. Tovecimig contains two single-chain variable fragments (scFv) that bind human DLL4, and these fragments are linked to the C-terminus of the heavy chain that binds human VEGF-A. Tovecimig blocks the DLL4/NOTCH1 and VEGF signaling pathways, inhibiting DLL4-mediated Notch signaling and VEGF-A-mediated angiogenic signaling in tumor angiogenesis. Tovecimig can be used in research on refractory metastatic colorectal cancer, advanced biliary tract cancer, solid tumors, gastric cancer, and colon cancer[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tovecimig | 97.39% | Tovecimig (CTX-009) is a bispecific antibody targeting DLL4 and VEGF-A. Tovecimig contains two single-chain variable fragments (scFv) that bind human DLL4, and these fragments are linked to the C-terminus of the heavy chain that binds human VEGF-A. Tovecimig blocks the DLL4/NOTCH1 and VEGF signaling pathways, inhibiting DLL4-mediated Notch signaling and VEGF-A-mediated angiogenic signaling in tumor angiogenesis. Tovecimig can be used in research on refractory metastatic colorectal cancer, advanced biliary tract cancer, solid tumors, gastric cancer, and colon cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Minal A. Barve, et al. Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003). J Clin Oncol 44, 125(2026). Volume 44, Number 2_suppl.
-
[2].
Ian Hu, et al. CTX-009 (tovecimig) with gemcitabine, cisplatin, and
durvalumab as first-line therapy in patients with unresectable
or metastatic biliary tract cancers. - [3]. Na JY, et al. Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. Cancer science. 2024 Dec;115(12):3943-3951.
-
[4].
Diana I. Albu, et al. The combination of DLL4/VEGF-a blockade and immunomodulation can eliminate MHC class I negative tumors in mice. Cancer Res (2024) 84. - [5]. Yeom DH, et al. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. Int J Mol Sci. 2020 Dec 29;22(1):241.
